297 related articles for article (PubMed ID: 7565947)
21. Long-term experience with lamivudine therapy for hepatitis B virus infection after liver transplantation.
Ben-Ari Z; Mor E; Shapira Z; Tur-Kaspa R
Liver Transpl; 2001 Feb; 7(2):113-7. PubMed ID: 11172394
[TBL] [Abstract][Full Text] [Related]
22. Fatal lactic acidosis associated with highly active antiretroviral therapy in patients with advanced human immunodeficiency virus infection in Taiwan.
Sheng WH; Hsieh SM; Lee SC; Chen MY; Wang JT; Hung CC; Chang SC
Int J STD AIDS; 2004 Apr; 15(4):249-53. PubMed ID: 15075019
[TBL] [Abstract][Full Text] [Related]
23. Severe toxicity of fialuridine (FIAU).
Bari A
N Engl J Med; 1996 Apr; 334(17):1135; author reply 1137-8. PubMed ID: 8598879
[No Abstract] [Full Text] [Related]
24. A multicenter study of lamivudine treatment in 33 patients with hepatitis B after liver transplantation.
Fontana RJ; Hann HW; Wright T; Everson G; Baker A; Schiff ER; Riely C; Anschuetz G; Riker-Hopkins M; Brown N;
Liver Transpl; 2001 Jun; 7(6):504-10. PubMed ID: 11443577
[TBL] [Abstract][Full Text] [Related]
25. Lamivudine as initial treatment for chronic hepatitis B in the United States.
Dienstag JL; Schiff ER; Wright TL; Perrillo RP; Hann HW; Goodman Z; Crowther L; Condreay LD; Woessner M; Rubin M; Brown NA
N Engl J Med; 1999 Oct; 341(17):1256-63. PubMed ID: 10528035
[TBL] [Abstract][Full Text] [Related]
26. Short-term entecavir therapy of chronic severe hepatitis B.
Chen J; Han JH; Liu C; Yu RH; Li FZ; Li QF; Gong GZ
Hepatobiliary Pancreat Dis Int; 2009 Jun; 8(3):261-6. PubMed ID: 19502165
[TBL] [Abstract][Full Text] [Related]
27. Ganciclovir treatment of hepatitis B virus infection in liver transplant recipients.
Gish RG; Lau JY; Brooks L; Fang JW; Steady SL; Imperial JC; Garcia-Kennedy R; Esquivel CO; Keeffe EB
Hepatology; 1996 Jan; 23(1):1-7. PubMed ID: 8550028
[TBL] [Abstract][Full Text] [Related]
28. Severe toxicity of fialuridine (FIAU).
Prince AM
N Engl J Med; 1996 Apr; 334(17):1136; author reply 1137-8. PubMed ID: 8598882
[No Abstract] [Full Text] [Related]
29. A multi-center open study to determine the effect of lamivudine on HBV DNA clearance and to assess the safety of the regimen in patients with chronic hepatitis B infection.
Mazur W; Król F; Cianciara J; Nazzal K; Gładysz A; Juszczyk J; Bolewska B; Adamek J; Czajka B; Swietek K; Kryczka W; Gonciarz Z
Med Sci Monit; 2002 Apr; 8(4):CR257-62. PubMed ID: 11951067
[TBL] [Abstract][Full Text] [Related]
30. A comparison of entecavir and lamivudine for HBeAg-positive chronic hepatitis B.
Chang TT; Gish RG; de Man R; Gadano A; Sollano J; Chao YC; Lok AS; Han KH; Goodman Z; Zhu J; Cross A; DeHertogh D; Wilber R; Colonno R; Apelian D;
N Engl J Med; 2006 Mar; 354(10):1001-10. PubMed ID: 16525137
[TBL] [Abstract][Full Text] [Related]
31. Recurrence of hepatitis B in liver transplants treated with antiviral therapy.
Marzano A; Debernardi-Venon W; Smedile A; Brunetto MR; Torrani Cerenzia MR; Actis GC; Zamboni F; Ghisetti V; Piantino P; David E; Salizzoni M; Rizzetto M
Ital J Gastroenterol Hepatol; 1998 Feb; 30(1):77-81. PubMed ID: 9615271
[TBL] [Abstract][Full Text] [Related]
32. Multicenter study of lamivudine therapy for hepatitis B after liver transplantation. Lamivudine Transplant Group.
Perrillo R; Rakela J; Dienstag J; Levy G; Martin P; Wright T; Caldwell S; Schiff E; Gish R; Villeneuve JP; Farr G; Anschuetz G; Crowther L; Brown N
Hepatology; 1999 May; 29(5):1581-6. PubMed ID: 10216146
[TBL] [Abstract][Full Text] [Related]
33. Outcome of lamivudine resistant hepatitis B virus mutant post-liver transplantation on lamivudine monoprophylaxis.
Chan HL; Chui AK; Lau WY; Chan FK; Hui AY; Rao AR; Wong J; Lai EC; Sung JJ
Clin Transplant; 2004 Jun; 18(3):295-300. PubMed ID: 15142051
[TBL] [Abstract][Full Text] [Related]
34. A double-blind placebo-controlled study of emtricitabine in chronic hepatitis B.
Lim SG; Ng TM; Kung N; Krastev Z; Volfova M; Husa P; Lee SS; Chan S; Shiffman ML; Washington MK; Rigney A; Anderson J; Mondou E; Snow A; Sorbel J; Guan R; Rousseau F;
Arch Intern Med; 2006 Jan; 166(1):49-56. PubMed ID: 16401810
[TBL] [Abstract][Full Text] [Related]
35. Residual hepatitis B virus particles in liver transplant recipients receiving lamivudine: PCR quantitation of HBV DNA and ELISA of preS1 antigen.
Petit MA; Buffello-Le Guillou D; Roche B; Dussaix E; Duclos-Vallée JC; Féray C; Samuel D
J Med Virol; 2001 Nov; 65(3):493-504. PubMed ID: 11596084
[TBL] [Abstract][Full Text] [Related]
36. Lamivudine therapy for spontaneously occurring severe acute exacerbation in chronic hepatitis B virus infection: a preliminary study.
Tsubota A; Arase Y; Saitoh S; Kobayashi M; Suzuki Y; Suzuki F; Chayama K; Murashima N; Ikeda K; Kobayashi M; Kumada H
Am J Gastroenterol; 2001 Feb; 96(2):557-62. PubMed ID: 11232706
[TBL] [Abstract][Full Text] [Related]
37. [Relation of serological markers of hepatitis B virus and alanine transaminase to hepatic tissue pathology in patients with chronic hepatitis B].
Yang XY; Wen FY; Wu JL; Zhou HJ
Nan Fang Yi Ke Da Xue Xue Bao; 2006 Jun; 26(6):892-3. PubMed ID: 16793626
[TBL] [Abstract][Full Text] [Related]
38. Detecting life-threatening lactic acidosis related to nucleoside-analog treatment of human immunodeficiency virus-infected patients, and treatment with L-carnitine.
Claessens YE; Cariou A; Monchi M; Soufir L; Azoulay E; Rouges P; Goldgran-Toledano D; Branche F; Dhainaut JF
Crit Care Med; 2003 Apr; 31(4):1042-7. PubMed ID: 12682470
[TBL] [Abstract][Full Text] [Related]
39. Severe toxicity of fialuridine (FIAU).
Josephson L
N Engl J Med; 1996 Apr; 334(17):1135-6; author reply 1137-8. PubMed ID: 8598880
[No Abstract] [Full Text] [Related]
40. New nucleoside analogues for chronic hepatitis B.
Schalm SW; de Man RA; Heijtink RA; Niesters HG
J Hepatol; 1995; 22(1 Suppl):52-6. PubMed ID: 7602078
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
